Jefferies Financial Group Increases Astria Therapeutics (NASDAQ:ATXS) Price Target to $27.00

Astria Therapeutics (NASDAQ:ATXS) had its price objective hoisted by Jefferies Financial Group from $22.00 to $27.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on ATXS. Wedbush reissued an outperform rating and set a $17.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 5th. HC Wainwright reissued a buy rating and set a $18.00 price target on shares of Astria Therapeutics in a research note on Monday.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $14.08 on Monday. The stock has a market capitalization of $772.72 million, a PE ratio of -6.01 and a beta of 0.72. The business has a 50 day simple moving average of $13.68 and a two-hundred day simple moving average of $8.79. Astria Therapeutics has a 1-year low of $4.26 and a 1-year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, analysts anticipate that Astria Therapeutics will post -1.72 EPS for the current fiscal year.

Insider Transactions at Astria Therapeutics

In other Astria Therapeutics news, Director Perceptive Advisors Llc bought 2,481,350 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $29,999,521.50. Following the purchase, the director now directly owns 4,873,721 shares in the company, valued at $58,923,286.89. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Astria Therapeutics news, insider Christopher Morabito sold 9,200 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Perceptive Advisors Llc purchased 2,481,350 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were purchased at an average price of $12.09 per share, for a total transaction of $29,999,521.50. Following the purchase, the director now owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The disclosure for this purchase can be found here. Corporate insiders own 3.40% of the company’s stock.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 36.1% in the fourth quarter. Vanguard Group Inc. now owns 2,055,707 shares of the biotechnology company’s stock worth $15,788,000 after buying an additional 545,786 shares during the last quarter. American International Group Inc. raised its holdings in Astria Therapeutics by 29.0% in the 4th quarter. American International Group Inc. now owns 16,443 shares of the biotechnology company’s stock worth $126,000 after purchasing an additional 3,694 shares during the period. Perceptive Advisors LLC raised its holdings in Astria Therapeutics by 82.9% in the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares during the period. Legal & General Group Plc raised its holdings in Astria Therapeutics by 34.4% in the 4th quarter. Legal & General Group Plc now owns 3,492 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 894 shares during the period. Finally, Barclays PLC raised its holdings in Astria Therapeutics by 487.0% in the 4th quarter. Barclays PLC now owns 49,414 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 40,996 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.